Product Specifications: Lyophilized Powder (>99% purity) in 3ml vial. *Requires Reconstitution ** Available for bulk custom order with 57 Cap/Crimp colors to choose from.
Application: Research peptide evaluated in obesity and weight loss studies
Chemical Formula: C194H312N54O59S2
CAS Number: 1415456-99-3
Molecular Weight: ~4409.01 g/mol
Concentration: ≥99%
Cagrilintide is a long-acting acylated amylin analogue that acts as a non-selective amylin receptor (AMYR) agonist and calcitonin G protein-coupled receptor (CTR) agonist 1. Initially mischaracterized as a dual GIP/GLP-1 receptor agonist, it is being extensively researched both as a standalone treatment and in combination with semaglutide (known as CagriSema) for multiple therapeutic applications.
Clinical Benefits
1. Weight Management Benefits
- Substantial weight reduction potential as monotherapy
- Enhanced weight loss when combined with semaglutide
- High completion rates in clinical trials demonstrating good tolerability
2. Metabolic Benefits
- Improved glycemic control
- Better fasting plasma glucose regulation
- Potential cardiovascular risk reduction
3. Safety Profile
- Comparable treatment-emergent adverse events to existing therapies
- Lower incidence of vomiting compared to GLP-1 receptor agonists
- Well-tolerated in clinical trials
Primary Research Applications
1. Obesity Management
The primary focus of cagrilintide research is obesity treatment:
- As monotherapy: Demonstrates comparable weight loss to established treatments like semaglutide/liraglutide
- In combination (CagriSema): Shows superior weight loss outcomes:
- 22.7% weight reduction in non-diabetic obese patients over 68 weeks
- 15.7% weight reduction in patients with type 2 diabetes over 68 weeks
- Up to 40.4% of patients achieving ≥25% weight loss with CagriSema
2. Type 2 Diabetes Treatment
Cagrilintide is being investigated for glycemic control:
- Shows promise in managing diabesity (diabetes with obesity)
- Demonstrates improved fasting plasma glucose levels compared to standard treatments
- Exhibits complementary effects when combined with semaglutide for glycemic control
Mechanism of Action
1. Primary Mechanisms
- Functions as a non-selective amylin receptor agonist
- Induces satiety through multiple pathways:
- Delayed gastric emptying
- Actions on specific brain regions
- Activation of both amylin receptors and calcitonin receptors
2. Advantages Over Existing Treatments
- Once-weekly subcutaneous administration versus multiple daily injections required for other amylin analogues
- Lower incidence of gastrointestinal side effects, particularly vomiting, compared to GLP-1 receptor agonists
References:
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: A randomised, controlled, phase 1b trial. The Lancet, 398(10295), 239-249. https://doi.org/10.1016/S0140-6736(21)01089-6
Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., & Rubino, D. M. (2023). Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet, 401(10375), 451-464. https://doi.org/10.1016/S0140-6736(23)00022-5
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Satylganova, A., & Wilding, J. P. H. (2022). Effects of cagrilintide (AM833), a novel amylin analogue, on gastric emptying and appetite in individuals with obesity: A randomised, placebo-controlled trial. Diabetes, Obesity and Metabolism, 24(8), 1551-1560. https://doi.org/10.1111/dom.14715
Disclaimer: This product is intended solely for laboratory research purposes. It is not suitable for consumption by humans, nor for medical, veterinary, or household purposes. Researchers should handle all peptides with care and adhere to strict safety guidelines during experiments. Only qualified professionals with appropriate expertise should manage and handle this product. The distributor, manufacturer, and seller of this product are not responsible for misuse or any resulting consequences. By accessing this product, you consent to comply with these terms and conditions.
